Last reviewed · How we verify
Lasofoxifene in combination with abemaciclib
Lasofoxifene is a selective estrogen receptor modulator (SERM) that blocks estrogen signaling, combined with abemaciclib, a CDK4/6 inhibitor that prevents cell cycle progression in hormone receptor-positive breast cancer cells.
Lasofoxifene is a selective estrogen receptor modulator (SERM) that blocks estrogen signaling, combined with abemaciclib, a CDK4/6 inhibitor that prevents cell cycle progression in hormone receptor-positive breast cancer cells. Used for Hormone receptor-positive, HER2-negative breast cancer (postmenopausal women).
At a glance
| Generic name | Lasofoxifene in combination with abemaciclib |
|---|---|
| Sponsor | Sermonix Pharmaceuticals Inc. |
| Drug class | SERM + CDK4/6 inhibitor combination |
| Target | Estrogen receptor (ER) + CDK4/6 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Lasofoxifene acts as an estrogen receptor antagonist in breast tissue, blocking growth signals driven by estrogen in hormone receptor-positive (HR+) breast cancer. Abemaciclib inhibits cyclin-dependent kinases 4 and 6, preventing the G1/S cell cycle checkpoint and halting cancer cell proliferation. Together, they provide dual inhibition of estrogen-driven growth and cell cycle progression.
Approved indications
- Hormone receptor-positive, HER2-negative breast cancer (postmenopausal women)
Common side effects
- Neutropenia
- Diarrhea
- Fatigue
- Nausea
- Infection
Key clinical trials
- Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation (PHASE3)
- Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: